Iridex Corp (IRIX) Stock Price, Quote & News

Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems th...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 940 4700

Fax: 650 940 4710

Website: www.iridex.com

Address:

1212 Terra Bella Avenue, Mountain View, United States

alexpitti Aug. 19 at 1:27 AM

really strong quarter for $IRIX, but i have no shares because i don't understand how novel can steal 2 million shares #stopthesteal

1 · Reply

EarningsInsider Aug. 18 at 9:46 PM

https://www.marketbeat.com/earnings/reports/2026-8-18-iridex-co-stock/ $IRIX IRIDEX Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 18 at 9:02 PM

$IRIX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.07 down -16.67% YoY • Reported revenue of $12.57M down -7.41% YoY

0 · Reply

islandpunk Aug. 18 at 8:16 PM

$IRIX https://www.stocktitan.net/news/IRIX/iridex-reports-second-quarter-2026-financial-m4b19qpmmudf.html

0 · Reply

Zephix Aug. 18 at 3:03 PM

$IRIX Medical-device company focused on glaucoma and retinal disease lasers…

0 · Reply

StudBull Aug. 13 at 1:48 PM

$IRIX How does a former CEO engage in an apparent (and possibly illegal) proxy scheme without understanding the company’s corporate bylaws?

1 · Reply

JustBen47 Aug. 1 at 11:41 PM

$IRIX Full-year 2025 revenue grew to $52.7 million from $48.7 million in 2024 helped by growth in both glaucoma and retina product lines.

0 · Reply

alexpitti Jul. 30 at 7:53 PM

$IRIX now what

2 · Reply

StudBull Jul. 30 at 5:56 PM

$IRIX after the recent 8-K and 13d disclosures I’m hoping Novell/Clinico is talking directly with management, and not through Will Moore

1 · Reply

10baggerPete Jul. 22 at 12:54 PM

$IRIX Romeo is bleeding! How to value such an unusul situation. A company update would be helpful.

0 · Reply

IRIDEX Earnings Call Transcript: Q2 2026

Aug 18, 2026, 5:00 PM EDT - 2 days ago

IRIDEX Earnings release: Q2 2026

Aug 18, 2026, 5:00 PM EDT - 2 days ago

IRIDEX Quarterly report: Q2 2026

Aug 18, 2026, 4:05 PM EDT - 2 days ago

Iridex Reports Second Quarter 2026 Financial Results

Aug 4, 2026, 4:05 PM EDT - 16 days ago

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

Jul 20, 2026, 7:00 AM EDT - 4 weeks ago

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

Jun 17, 2026, 7:00 PM EDT - 2 months ago

IRIDEX Transcript: Planet MicroCap Las Vegas 2026

Jun 9, 2026, 4:05 PM EDT - 2 months ago

Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference

Jun 1, 2026, 7:00 AM EDT - 2 months ago

IRIDEX Slides: Investor presentation

May 28, 2026, 10:45 AM EDT - 3 months ago

IRIDEX Transcript: Lytham Partners Spring 2026 Investor Conference

May 19, 2026, 5:00 PM EDT - 3 months ago

IRIDEX Earnings Call Transcript: Q1 2026

May 19, 2026, 5:00 PM EDT - 3 months ago

IRIDEX Earnings release: Q1 2026

May 19, 2026, 5:00 PM EDT - 3 months ago

IRIDEX Quarterly report: Q1 2026

May 19, 2026, 4:05 PM EDT - 3 months ago

Iridex Reports First Quarter 2026 Financial Results

May 5, 2026, 4:05 PM EDT - 3 months ago

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

Apr 24, 2026, 8:00 AM EDT - 4 months ago

IRIDEX Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

IRIDEX Proxy statement: Proxy filing

2026-04-07T20:11:08.000Z - 4 months ago

Iridex announces new partnership with EyeProGPO

Apr 7, 2026, 4:05 PM EDT - 4 months ago

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

2026-03-27T12:55:42.000Z - 5 months ago

Iridex price target lowered to $2.75 from $3 at Alliance Global

Mar 26, 2026, 5:00 PM EDT - 5 months ago

IRIDEX Earnings Call Transcript: Q4 2025

Mar 26, 2026, 5:00 PM EDT - 5 months ago

IRIDEX Annual report: Q4 2025

Mar 26, 2026, 5:00 PM EDT - 5 months ago

IRIDEX Earnings release: Q4 2025

Mar 26, 2026, 4:05 PM EDT - 5 months ago

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 12, 2026, 4:05 PM EDT - 5 months ago

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

2026-02-05T15:55:28.000Z - 7 months ago

Iridex initiated with a Buy at Alliance Global

2026-02-02T12:11:18.000Z - 7 months ago

Iridex announces plans to relocate headquarters

Feb 2, 2026, 7:00 AM EST - 7 months ago

Iridex Announces Plans to Relocate Headquarters

2026-01-12T12:11:16.000Z - 7 months ago

Iridex reports preliminary Q4 revenue $14.6M-$14.8M

Jan 12, 2026, 7:00 AM EST - 7 months ago

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

Dec 11, 2025, 10:45 AM EST - 9 months ago

IRIDEX Transcript: Sidoti's Year End Virtual Investor Conference

2025-12-11T12:21:06.000Z - 9 months ago

Iridex’s MicroPulse technology shows efficacy in glaucoma management study

Dec 11, 2025, 7:00 AM EST - 9 months ago

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

2025-12-08T12:11:03.000Z - 9 months ago

Iridex announces new study in TVST on glaucoma treatments

Dec 8, 2025, 7:00 AM EST - 9 months ago

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment

Dec 5, 2025, 7:00 AM EST - 9 months ago

Iridex to Present at the Sidoti Year-End Virtual Investor Conference

Nov 11, 2025, 5:00 PM EST - 10 months ago

IRIDEX Earnings Call Transcript: Q3 2025

Nov 11, 2025, 5:00 PM EST - 10 months ago

IRIDEX Quarterly report: Q3 2025

Nov 11, 2025, 5:00 PM EST - 10 months ago

IRIDEX Earnings release: Q3 2025

Nov 11, 2025, 4:05 PM EST - 10 months ago

Iridex Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 4:05 PM EDT - 10 months ago

Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025

2025-09-09T20:45:21.000Z - 1 year ago

Iridex regains compliance with Nasdaq listing requirements

Sep 9, 2025, 4:05 PM EDT - 1 year ago

Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance

Aug 12, 2025, 5:00 PM EDT - 1 year ago

IRIDEX Earnings Call Transcript: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 1 year ago

IRIDEX Quarterly report: Q2 2025

Aug 12, 2025, 5:00 PM EDT - 1 year ago

IRIDEX Earnings release: Q2 2025

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Iridex Reports Second Quarter 2025 Financial Results

2025-06-24T11:05:24.000Z - 1 year ago

Iridex announces first patient enrolled in investigator-led study of MicroPulse

Jun 24, 2025, 7:00 AM EDT - 1 year ago

Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema

Jun 2, 2025, 8:00 AM EDT - 1 year ago

IRIDEX Proxy statement: Proxy Filing

May 20, 2025, 8:00 AM EDT - 1 year ago

IRIDEX Proxy statement: Proxy Filing

May 20, 2025, 8:00 AM EDT - 1 year ago

IRIDEX Proxy statement: Proxy Filing

May 13, 2025, 5:00 PM EDT - 1 year ago

IRIDEX Earnings Call Transcript: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

IRIDEX Quarterly report: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

IRIDEX Earnings release: Q1 2025

May 13, 2025, 4:05 PM EDT - 1 year ago

Iridex Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Iridex to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

IRIDEX Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

IRIDEX Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

IRIDEX Proxy statement: Proxy Filing

Apr 16, 2025, 5:00 PM EDT - 1 year ago

IRIDEX Transcript: Status Update

Apr 9, 2025, 4:05 PM EDT - 1 year ago

Iridex to Host Strategic Vision Call on April 16, 2025

Mar 27, 2025, 5:00 PM EDT - 1 year ago

IRIDEX Earnings Call Transcript: Q4 2024

Mar 27, 2025, 5:00 PM EDT - 1 year ago

IRIDEX Annual report: Q4 2024

Mar 27, 2025, 5:00 PM EDT - 1 year ago

IRIDEX Earnings release: Q4 2024

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Iridex Reports Fourth Quarter and Full Year 2024 Financial Results

2025-03-19T13:26:13.000Z - 1 year ago

Iridex appoints Romeo Dizon as CFO

Mar 19, 2025, 9:15 AM EDT - 1 year ago

Iridex Announces Strategic Investment in the Company

2025-03-14T11:05:22.000Z - 1 year ago

Iridex ‘not aware of any material developments’ precipitating volatility

Mar 14, 2025, 7:00 AM EDT - 1 year ago

Iridex Comments on Recent Stock Price Volatility

Mar 13, 2025, 5:00 PM EDT - 1 year ago

Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

2025-01-14T12:05:28.000Z - 1 year ago

Iridex sees Q4 revenue $12.6M-$12.7M vs. $12.5M last year

2024-12-18T21:25:10.000Z - 1 year ago

Iridex publishes MicroPulse Transscleral Laser Therapy study

Dec 18, 2024, 4:05 PM EST - 1 year ago

Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

2024-11-19T13:25:19.000Z - 1 year ago

Iridex comments on changing glaucoma reimbursement landscape

Nov 19, 2024, 8:14 AM EST - 1 year ago

Iridex Comments on Changing Glaucoma Reimbursement Landscape

Nov 12, 2024, 5:00 PM EST - 1 year ago

IRIDEX Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

IRIDEX Quarterly report: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

IRIDEX Earnings release: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024

2024-10-05T07:01:36.000Z - 2 years ago

Iridex CEO David Bruce to transition out of company, Patrick Mercer to succeed

Oct 3, 2024, 4:05 PM EDT - 2 years ago

Iridex Appoints Patrick Mercer as Chief Executive Officer

2024-09-05T20:11:46.000Z - 2 years ago

Iridex files ot sell 4.95M shares of common stock for holders

Sep 5, 2024, 8:00 AM EDT - 2 years ago

IRIDEX Registration statement: Registration Filing

2024-08-08T21:07:49.000Z - 2 years ago

Iridex reports Q2 EPS (16c), one-estimate (12c)

Aug 8, 2024, 5:00 PM EDT - 2 years ago

IRIDEX Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

IRIDEX Quarterly report: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

IRIDEX Earnings release: Q2 2024

2024-08-05T12:12:08.000Z - 2 years ago

Iridex announces convertible note financing

May 14, 2024, 5:00 PM EDT - 2 years ago

IRIDEX Earnings Call Transcript: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

IRIDEX Quarterly report: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

IRIDEX Earnings release: Q1 2024

May 14, 2024, 4:05 PM EDT - 2 years ago

Iridex Reports First Quarter 2024 Financial Results

Apr 29, 2024, 8:00 AM EDT - 2 years ago

IRIDEX Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

IRIDEX Proxy statement: Proxy Filing

Mar 26, 2024, 5:00 PM EDT - 2 years ago

IRIDEX Earnings Call Transcript: Q4 2023

Mar 26, 2024, 5:00 PM EDT - 2 years ago

IRIDEX Annual report: Q4 2023

Mar 26, 2024, 5:00 PM EDT - 2 years ago

IRIDEX Earnings release: Q4 2023

Mar 26, 2024, 4:05 PM EDT - 2 years ago

Iridex Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024

Jan 24, 2024, 8:00 AM EST - 2 years ago

Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

Jan 11, 2024, 6:45 PM EST - 2 years ago

Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma

Dec 28, 2023, 6:00 PM EST - 2 years ago

Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation

Nov 27, 2023, 9:00 AM EST - 2 years ago

Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation

Nov 15, 2023, 10:20 AM EST - 3 years ago

IRIDEX Transcript: The Stifel 2023 Annual Healthcare Conference

Nov 14, 2023, 5:00 PM EST - 3 years ago

IRIDEX Earnings Call Transcript: Q3 2023

Nov 14, 2023, 5:00 PM EST - 3 years ago

IRIDEX Quarterly report: Q3 2023

Nov 14, 2023, 5:00 PM EST - 3 years ago

IRIDEX Earnings release: Q3 2023

Nov 14, 2023, 4:21 PM EST - 3 years ago

Iridex Reports Third Quarter 2023 Financial Results and Business Update

Nov 13, 2023, 9:00 AM EST - 3 years ago

Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023

Oct 26, 2023, 4:22 PM EDT - 3 years ago

Iridex to Report Third Quarter Financial Results on November 14, 2023

Aug 29, 2023, 4:05 PM EDT - 3 years ago

Iridex Announces Strategic Review to Unlock Shareholder Value

Aug 10, 2023, 5:00 PM EDT - 3 years ago

IRIDEX Earnings Call Transcript: Q2 2023

Aug 10, 2023, 5:00 PM EDT - 3 years ago

IRIDEX Quarterly report: Q2 2023

Aug 10, 2023, 5:00 PM EDT - 3 years ago

IRIDEX Earnings release: Q2 2023

May 24, 2023, 8:00 AM EDT - 3 years ago

IRIDEX Proxy statement: Proxy Filing

May 11, 2023, 5:00 PM EDT - 3 years ago

IRIDEX Earnings Call Transcript: Q1 2023

May 11, 2023, 5:00 PM EDT - 3 years ago

IRIDEX Quarterly report: Q1 2023

May 11, 2023, 5:00 PM EDT - 3 years ago

IRIDEX Earnings release: Q1 2023

Apr 28, 2023, 8:00 AM EDT - 3 years ago

IRIDEX Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

IRIDEX Proxy statement: Proxy Filing

Apr 27, 2023, 4:05 PM EDT - 3 years ago

Iridex to Report First Quarter Financial Results on May 11, 2023

Apr 7, 2023, 8:00 AM EDT - 3 years ago

IRIDEX Proxy statement: Proxy Filing

Mar 9, 2023, 5:00 PM EST - 3 years ago

IRIDEX Earnings Call Transcript: Q4 2022

Mar 9, 2023, 5:00 PM EST - 3 years ago

IRIDEX Earnings release: Q4 2022

Mar 9, 2023, 5:00 PM EST - 3 years ago

IRIDEX Annual report: Q4 2022

Mar 9, 2023, 4:05 PM EST - 3 years ago

Iridex Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 7, 2023, 4:05 PM EST - 3 years ago

Iridex to Present at the 35th Annual Roth Conference

Mar 2, 2023, 9:00 AM EST - 3 years ago

Iridex Introduces New Research and Showcases Five Events at the AGS Meeting

Feb 23, 2023, 4:05 PM EST - 3 years ago

Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

Jan 10, 2023, 4:05 PM EST - 3 years ago

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022

Dec 6, 2022, 5:07 PM EST - 4 years ago

Iridex to Participate in Fireside Chat with Stifel Equity Research

Nov 10, 2022, 12:00 PM EST - 4 years ago

IRIDEX Earnings Call Transcript: Q3 2022

Nov 10, 2022, 12:00 PM EST - 4 years ago

IRIDEX Quarterly report: Q3 2022

Sep 29, 2022, 4:05 PM EDT - 4 years ago

Iridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022

Aug 18, 2022, 4:05 PM EDT - 4 years ago

Iridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

alexpitti Aug. 19 at 1:27 AM

really strong quarter for $IRIX, but i have no shares because i don't understand how novel can steal 2 million shares #stopthesteal

1 · Reply

EarningsInsider Aug. 18 at 9:46 PM

https://www.marketbeat.com/earnings/reports/2026-8-18-iridex-co-stock/ $IRIX IRIDEX Earnings Transcript

0 · Reply

StocktwitsEarnings Aug. 18 at 9:02 PM

$IRIX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.07 down -16.67% YoY • Reported revenue of $12.57M down -7.41% YoY

0 · Reply

islandpunk Aug. 18 at 8:16 PM

$IRIX https://www.stocktitan.net/news/IRIX/iridex-reports-second-quarter-2026-financial-m4b19qpmmudf.html

0 · Reply

Zephix Aug. 18 at 3:03 PM

$IRIX Medical-device company focused on glaucoma and retinal disease lasers…

0 · Reply

StudBull Aug. 13 at 1:48 PM

$IRIX How does a former CEO engage in an apparent (and possibly illegal) proxy scheme without understanding the company’s corporate bylaws?

1 · Reply

JustBen47 Aug. 1 at 11:41 PM

$IRIX Full-year 2025 revenue grew to $52.7 million from $48.7 million in 2024 helped by growth in both glaucoma and retina product lines.

0 · Reply

alexpitti Jul. 30 at 7:53 PM

$IRIX now what

2 · Reply

StudBull Jul. 30 at 5:56 PM

$IRIX after the recent 8-K and 13d disclosures I’m hoping Novell/Clinico is talking directly with management, and not through Will Moore

1 · Reply

10baggerPete Jul. 22 at 12:54 PM

$IRIX Romeo is bleeding! How to value such an unusul situation. A company update would be helpful.

0 · Reply

StudBull Jul. 21 at 1:42 AM

$IRIX I must confess that reading about the alleged “stealth proxy” scheme in the 8-k reminds me of Vito getting caught in the Sopranos

0 · Reply

alexpitti Jul. 20 at 3:20 PM

it's such a wild battle for the company. i don't have any friends who know wtf $IRIX is so it's like i'm at a movie alone

0 · Reply

alexpitti Jul. 20 at 12:07 AM

$IRIX william moore doesn't want to talk to me about iridex. We've called 2 or 3 times. 🤮

1 · Reply

kamleshnaik Jul. 18 at 12:05 AM

$IRIX Tell him he is harming interst of small investors

0 · Reply

alexpitti Jul. 17 at 2:46 AM

$IRIX i need to have a call with william moore

1 · Reply

alexpitti Jul. 16 at 1:43 PM

$IRIX why is this down huge

1 · Reply

StudBull Jul. 14 at 7:46 PM

$IRIX Novell filed a SEC 13d amendment yesterday (1/13) disclosing that Xinpo Venture Capital, another entity controlled by Novell Inspiration’s founder/family bought 1.186M $IRIX public shares via open market purchases, increasing their combined ownership stake to 29.9%. Seems like an activist move? Anyone have any thoughts on this new disclosure?

0 · Reply

twixbarrtwits Jun. 17 at 1:02 AM

$IRIX 1.19

0 · Reply

AZOZ Jun. 15 at 5:16 PM

$IRIX Insider activity!

0 · Reply

Jackprong Jun. 4 at 4:17 PM

$IRIX Undervalued!

0 · Reply

Market Cap	13.63M
Revenue (ttm)	52.68M
Net Income (ttm)	-4.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-8.43%
Debt to Equity Ratio	0.80

Volume	121,800
Avg Vol	62,750
Day's Range	N/A - N/A
Shares Out	17.41M
Stochastic %K	22%
Beta	0.66
Analysts	Strong Buy
Price Target	$2.75